Rosuvastatin calcium is a salt form of rosuvastatin with antilipidemia activity. Rosuvastatin Calcium classified in class two of Biopharmaceutics Clasification System (BCS)  has low solubility in water (17.96 mg / L) and high permeability. Based on this, rosuvastatin calcium needs to be formulated appropriately in order to produce high bioavailability and maximum therapeutic effect. The bioavailability of BCS 2 drug is determined by the dissolution rate of the drug in gastrointestinal fluid so that a technique is needed in formulating the drug. This study aims to develop a formulation technique for rosuvastatin calcium tablets through liquisolid technique and formation of inclusion complexes with β-cyclodextrin in order to increase the rate of dissolution. Tablet formulation with liquisolid technique was made with a concentration of 10% rosuvastatin calcium in propylene glycol, with a ratio of US2® (carrier) and Aerosil 200 (coating) made with a ratio of 10: 1 and 20: 1. In addition to the formulation with liquisolid technique, formulations were also carried out with the complex inclusion technique of rosuvastatin calcium-β-cyclodextrin using kneading method and freeze drying method with a mol ratio of 1: 1 and 1: 2. The liquisolid system and inclusion complexes formed were characterized using FTIR and SEM. Characterization results indicated changes in the form of polymorphous rosuvastatin calcium. Tablet formulations were made by direct compression using a liquisolid system and an inclusion complex equivalent to 10 mg of rosuvastatin calcium. Based on the results of the ANOVA statistical test and further LSD tests showed that calcium rosuvastatin tablets made with liquisolid and inclusion complexes can increase the dissolution rate compared to pure rosuvastatin calcium tablets and inovator rosuvastatin calcium tablets. The highest dissolution rate was produced by liquisolid R20: 1 tablet at 60 minutes at 85.53 ± 1.02% in an enzyme-free simulated gastric fluid dissolution medium and 110.02 ± 1.71% in an enzyme-free simulated intestinal fluid dissolution medium.

Dysbiosis is a condition where there is an imbalance in the number of microorganisms in the human digestive tract. Basically, in normal conditions, colonies of microorganisms tend to act as normal flora that helps the process of nutrition digestion and maintain the immune system. However, when the number of colonies increases significantly, the body will begin to experience various diseases symptoms. The occurrence of dysbiosis in the end will be able to cause systemic abnormalities, such as interference with the absorption of nutrients that potentially cause metabolic abnormalities. Probiotics are live microorganisms which when administered in appropriate doses will benefit the health of the host. The ability of probiotics in symbiosis with microorganisms that exist in the intestine can suppress the growth rate of harmful bacteria (pathogens), and in the end will be able to improve the immune system. Setiaratu area is an area that borders the location of Tasikmalaya Ministry of Health Poltekkes. In this community service, outreach activities and creation of leaflets about the importance of probiotics consumption as an effort to prevent the occurrence of dysbiosis has been conducted in the district of Setiaratu. This community service was carried out in conjunction with Community Service Program of Poltekkes Kemenkes Tasikmalaya. After this PKM activity, it is hoped that the public can be expected to increase knowledge about dysbiosis and the use of probiotics to prevent and curative dysbiosis, especially in Setiaratu area.